An interventional study of One-Finger Technique in Ovary Cancer, Cervical Cancer and Endometrial Cancer, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Supportive care
Para-aortic lymphadenectomy plays an important role in the surgical treatment of major gynecological malignancies (ovarian, endometrial, and cervical cancer). Identifying bilateral ureters is a crucial step, and dissecting the upper left ureter is particularly challenging with no standardized method. This study introduces an anatomical technique called the "One-Finger Technique" for this purpose. This prospective, single-arm exploratory study aims to evaluate the feasibility and safety of the "One-Finger Technique" during open para-aortic lymphadenectomy.
2,759 studies on the registry are indexed under Ovarian Neoplasms; 735 are open to participants now.
This study's planned enrollment of 40 is below the median of 59 across 2,075 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 478 studies on the registry; 279 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patients in this arm will receive the "One-Finger Technique" for dissecting and identifying the upper left ureter during para-aortic lymphadenectomy.
Procedure: One-Finger Technique
A specific anatomical dissection technique using a single finger to bluntly dissect the retroperitoneal space and identify the upper left ureter during open para-aortic lymphadenectomy.
Success rate of separating and identifying the upper left ureter within 5 minutes
The proportion of patients in whom the upper left ureter (up to the level of the left renal vein or the intersection of ovarian vessels) is successfully and clearly exposed without surrounding tissue obstruction, meeting the visual requirements for subsequent safe lymph node resection. The procedure is timed via video recording. The start time is when the surgeon's finger enters the space after the lower left ureter is identified; the end time is when the upper left ureter is completely exposed and visually confirmed by the surgeon.
Time frame: Intraoperative (Evaluated within 5 minutes during the specific surgical step)
Incidence of left ureter complications
The proportion of patients experiencing left ureter injuries. This includes intraoperative macroscopically visible ureteral contusion or rupture, and postoperative complications occurring within 30 days due to ischemia or injury, such as ureterovaginal fistula or ureteral stricture.
Time frame: Intraoperative and up to 30 days postoperatively
Incidence of adjacent vessel or organ injury
The rate of collateral damage occurring during the "One-Finger Technique" dissection that requires additional suturing or repair, such as adjacent vessel tearing/bleeding or bowel serosal tearing.
Time frame: Intraoperative
Blood loss during the target step
The estimated local blood volume lost specifically during the single process of dissecting and identifying the upper left ureter. Because this step is brief and bleeding is usually minimal, it is recorded using visual estimation.
Time frame: Intraoperative (Assessed immediately after the completion of the specific surgical step)
Conversion rate to traditional methods
The proportion of cases where the "One-Finger Technique" is abandoned in favor of traditional direct sharp dissection due to severe local adhesions, unclear anatomy, or high pushing resistance. This reflects the clinical applicability of the technique.
Time frame: Intraoperative
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for May 2028, 23 months after the start.
Of 251 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 23 months is below that.
Counting every sponsor, half of 257 studies reached it within 48 months; a quarter within 24 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →